Steven L Allen
Overview
Explore the profile of Steven L Allen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
3465
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee H, Haque S, Gupta R, Kolitz J, Allen S, Rai K, et al.
Lymphatics
. 2024 Dec;
2(2):50-78.
PMID: 39664277
CLL B cells express elevated pro-survival BCL2, and its selective inhibitor, venetoclax, significantly reduces leukemic cell load, leading to clinical remission. Nonetheless, relapses occur. This study evaluates the hypothesis that...
2.
Ferrer G, Palacios F, Chiu P, Wong K, Bueno-Costa A, Barrientos J, et al.
Leukemia
. 2024 Nov;
39(2):499-502.
PMID: 39578533
No abstract available.
3.
Boisclair S, Zhou E, Naing P, Thakur R, Jou E, Goldberg B, et al.
Leuk Res
. 2024 Jul;
143:107545.
PMID: 38963990
Venetoclax (Ven) combined with a hypomethylating agent (HMA) enhances survival in elderly/unfit acute myeloid leukemia (AML) patients, yet often necessitates regimen modifications due to intolerance. However, it is unclear how...
4.
Cyriac A, Allen S, Cyriac S, Jhaveri K
Kidney Med
. 2024 Jul;
6(7):100838.
PMID: 38947774
No abstract available.
5.
Mazzarello A, Fitch M, Cardillo M, Ng A, Bhuiya S, Sharma E, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835400
Chronic lymphocytic leukemia (CLL) clones contain subpopulations differing in time since the last cell division ("age"): recently born, proliferative (PF; CXCR4CD5), intermediate (IF; CXCR4CD5), and resting (RF; CXCR4CD5) fractions. Herein,...
6.
Kaufman M, Yan X, Li W, Ghia E, Langerak A, Rassenti L, et al.
Front Oncol
. 2022 Jul;
12:897280.
PMID: 35903706
Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively...
7.
Jung B, Ferrer G, Chiu P, Aslam R, Ng A, Palacios F, et al.
JCI Insight
. 2022 May;
7(12).
PMID: 35511436
Chronic lymphocytic leukemia (CLL) results from expansion of a CD5+ B cell clone that requires interactions with other cell types, including T cells. Moreover, patients with CLL have elevated levels...
8.
Calissano C, Damle R, Marsilio S, Yan X, Yancopoulos S, Hayes G, et al.
Mol Med
. 2022 Mar;
28(1):35.
PMID: 35291936
No abstract available.
9.
Bagnara D, Tang C, Brown J, Kasar S, Fernandes S, Colombo M, et al.
Front Oncol
. 2021 Jun;
11:640731.
PMID: 34113563
Analyses of IGHV gene mutations in chronic lymphocytic leukemia (CLL) have had a major impact on the prognostication and treatment of this disease. A hallmark of IGHV-mutation status is that...
10.
Ferrer G, Jung B, Chiu P, Aslam R, Palacios F, Mazzarello A, et al.
Leukemia
. 2021 May;
35(11):3163-3175.
PMID: 33935280
Cancer pathogenesis involves the interplay of tumor- and microenvironment-derived stimuli. Here we focused on the influence of an immunomodulatory cell type, myeloid-derived suppressor cells (MDSCs), and their lineage-related subtypes on...